First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response
- 13 November 2014
- journal article
- Published by Springer Science and Business Media LLC in Familial Cancer
- Vol. 14 (2), 309-316
- https://doi.org/10.1007/s10689-014-9771-y
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancerBritish Journal of Cancer, 2012
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsThe New England Journal of Medicine, 2011
- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinibKidney International, 2010
- Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell CarcinomaClinical Cancer Research, 2009
- Frequency of Von Hippel‐Lindau germline mutations in classic and non‐classic Von Hippel‐Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation‐dependent probe amplificationClinical Genetics, 2007
- pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor DevelopmentMolecular and Cellular Biology, 2004
- von Hippel-Lindau diseaseThe Lancet, 2003
- Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.2002
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature, 1999
- Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotypeHuman Mutation, 1995